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Sequencing HIV-neutralizing antibody exons and
introns reveals detailed aspects of lineage
maturation
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George Georgiou1,5,8
The developmental pathways of broadly neutralizing antibodies (bNAbs) against HIV are of
great importance for the design of immunogens that can elicit protective responses. Here we
show the maturation features of the HIV-neutralizing anti-V1V2 VRC26 lineage by simulta-
neously sequencing the exon together with the downstream intron of VRC26 members.
Using the mutational landscapes of both segments and the selection-free nature of the intron
region, we identify multiple events of amino acid mutational convergence in the
complementarity-determining region 3 (CDR3) of VRC26 members, and determine potential
intermediates with diverse CDR3s to a late stage bNAb from 2 years prior to its isolation.
Moreover, we functionally characterize the earliest neutralizing intermediates with critical
CDR3 mutations, with some emerging only 14 weeks after initial lineage detection and
containing only ~6% V gene mutations. Our results thus underscore the utility of analyzing
exons and introns simultaneously for studying antibody maturation and repertoire selection.
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The elicitation of HIV-1-speciﬁc broadly neutralizing anti-bodies (bNAbs) represents a major challenge1,2. A detailedunderstanding of how bNAbs mature from naive pre-
cursors in HIV-1-infected individuals has the potential to aid in
the design of vaccine immunogens3,4. Speciﬁcally, reconstructing
the timeline of the emergence of molecular properties that confer
neutralization breadth and identifying relevant intermediate
antibodies bearing these traits may provide chronological tem-
plates for immunogen design5,6. These phylogenetic timelines are
typically reconstructed from heavy chain exonic variable region
(VH) sequences obtained by the next-generation sequencing of
peripheral B cells7–10. However, the interpretation of antibody
developmental pathways can be confounded by a number of
issues including: (a) the presence of sequences with diverse heavy
chain CDR3s (CDRH3s)11, (b) inferring the correct unmutated
common ancestor (UCA)5,10, (c) multiple mutations at the same
site or convergent mutations12, (e) under-sampling13, (f)
sequencing and PCR error14, (g) computational phylogenetic
limitations15 and (h) the inappropriate use of binary trees for
antibody phylogeny16.
To remove as much uncertainty as possible in interpreting
lineage evolution, we developed an approach that capitalizes not
only on the sequence of the antibody exon but also on the
downstream intron between the J and C genes (J/C intron).
Extensive studies have established that somatic hypermutation
(SHM) continues for more than 1 kb downstream of the variable
region exon into the J/C intron. Mutations occur in the exon and
intron at the same rate of 1 mutation per ~103 bp per cell divi-
sion17–20. Importantly, unlike exonic mutations which are
subjected to selection for expression, folding, and antigen bind-
ing, mutations in the intron are not subject to selective
pressure17,21–25.
Here, we sought to utilize this methodology to identify pre-
viously unrecognized developmental characteristics of the HIV-
speciﬁc anti-V1V2 VRC26 bNAb lineage which was isolated from
donor CAP256 and sampled for more than 4 years7,26,27. First, we
aimed to discover and better understand the maturation timeline
of early functional intermediates preceding the emergence of long
CDRH3−stabilizing mutations and the development of the
broadest known VRC26 bNAbs. These intermediates might be
used for immunogen design but also to better delineate when
neutralization breadth began to arise and the minimum VH gene
mutation levels for achieving this breadth in this critical lineage
subsection. Second, we investigated whether developmental
complexities such as intraclonal mutational convergence were
occurring since there is no standard means for characterizing and
conﬁrming the presence of these phenomena using an exon alone,
particularly when under-sampling is likely. Third, we wanted to
better understand the phylogenetic relationship between VRC26
antibodies with highly diverse CDRH3s, particularly for con-
ﬁrming additional intermediates. This has been a signiﬁcant
challenge in the case of other HIV bNAb lineages10,28.
Here the use of both exon and intron phylogenies provides a
distinct mechanism for studying these detailed maturation char-
acteristics of the VRC26 lineage. The sequencing and informatics
analysis of the mutational landscape within these two genetic
segments enables the identiﬁcation of CDRH3 amino acid
mutations that emerge independently in multiple
VRC26 sublineages and provides a better understanding of the
phylogenetic relationship among bNAbs with highly divergent
CDRH3s and their intermediates. Importantly, the study of these
two phylogenies also resulted in the selection of early inter-
mediate antibodies that display increasing afﬁnity for an auto-
logous viral strain and increasing heterologous breadth within
14 weeks of the initial detection of the VRC26 lineage with only
~6% mutated VH gene. This approach provides a high resolution
of bNAb evolutionary trajectories that may be applied to HIV-1
immunogen design and beyond.
Results
Exonic and intronic mutations accumulate in the VRC26
lineage. To assess the extent and frequency of intronic mutations
in healthy individuals, we sequenced an ~550 bp segment of the
heavy chain J/C intron (JH/C intron) directly downstream from
heavy chain sequences with rearranged immunoglobulin heavy
chain J gene 6 (IGHJ6) genes starting from ~100,000 FACS-
sorted memory B cells (mBCs; CD3-CD20+CD19+IgD−CD27+)
(Fig. 1a). Some sites exhibited a mutation frequency of >10% up
to about 450 bp downstream into the intron (Fig. 1c). The
genomic DNA (gDNA) of FACS-sorted naive B cells (259,000
cells; CD3−CD20+CD19+IgD+CD27−) and mBCs (219,000
cells) from a healthy donor was then used to amplify all VH
antibody sequences extending from the framework region 1 (FR1)
to about 140 bp into the JH/C intron (Fig. 1b, Supplementary
Tables 1 and 2) (denoted from here on as VH+ JH/C amplicons).
As expected, the mutation frequency in both the VH gene and JH/
C intron segments were substantially greater in the mBC reper-
toire relative to the naive repertoire, with intron segments pos-
sessing overall higher levels of mutations (Fig. 1d, Supplementary
Fig. 1).
We applied this ampliﬁcation scheme to generate gDNA-
derived VH+ JH/C and analogous lambda light chain Vλ+ Jλ/C
amplicons (extending from the FR1 to ~230 bp into the Jλ/C
intron) for antibodies that are putative members of the VRC26
HIV-1-speciﬁc bNAb lineage from donor CAP256. Genomic
DNA from weeks 38, 48, 59, 119 and 206 after primary infection
(Supplementary Table 1) was used as template. The VRC26
lineage was likely elicited by superinfecting viral variants at week
34 after primary infection7,26,29. Antibody sequences using the
VRC26 germline immunoglobulin heavy chain V gene 3–30
(IGHV3–30) and germline immunoglobulin heavy chain J gene 3
(IGHJ3) and having ≥85% CDRH3 nucleotide identity to earlier
published VRC26 antibodies7,26 were assumed to be members of
the lineage (Supplementary Table 3). Light chain lineage
members were required to use the VRC26 germline immunoglo-
bulin lambda light chain V gene 1–51 (IGLV1–51) and
immunoglobulin lambda light chain J gene 1 (IGLJ1) and have
≥92% CDRL3 identity to previously published members7,26
(Supplementary Table 4). V gene and intron mutation loads
were plotted for the lineage sequences isolated at each time point.
As expected, sequences bearing higher intronic divergence
increased in number over time after infection. An increase in
intronic mutational divergence (Mann–Whitney U test) was most
apparent during the ﬁrst few time points for both heavy and light
chain sequences (Fig. 1e, f). While this ﬁnding indicates that
diversiﬁcation continued over time, negative selection was
previously shown to increase as time progressed to possibly
control for deleterious mutations due to this diversiﬁcation30.
CDRH3 mutational convergence in two unique sublineages. A
maximum-likelihood (ML)15 phylogenetic tree generated using
the VH exon segment of all putative lineage members and rooted
on the previously inferred UCA7 contains two signature upper
and lower major bifurcating branches7,26 (Fig. 2a). 31/33 VRC26
bNAbs previously isolated by single-cell sequencing, including all
of the most potent and broad (46–63% heterologous neutraliza-
tion breadth), fall within the lower major bifurcating branch7.
Molecular traits essential for this broad neutralization and present
in 25/31 of these lower branch bNAbs include a stabilizing dis-
ulﬁde bond in the CDRH3 (Cys100a and Cys100q mutations;
Kabat numbering) and an Arg97 that has been proposed to
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06424-6
2 NATURE COMMUNICATIONS |  (2018) 9:4136 | DOI: 10.1038/s41467-018-06424-6 | www.nature.com/naturecommunications
further stabilize the CDRH37,26. When the VH ML tree is high-
lighted for the presence of the CDRH3 cysteines that give rise to
the disulﬁde bond (Fig. 2b) or for the Arg97 mutation (Fig. 2c),
two distinct sublineages in the lower major bifurcating branch
become evident. One of these sublineages develops a disulﬁde
bond and the Arg97 mutation (Arg97+Disulﬁde sublineage),
while members of the other sublineage gain a disulﬁde bond but
instead generally retain the initial Gly97 of the UCA (Gly97+
disulﬁde sublineage). Additional mutations outside of the
CDRH3 also serve to differentiate between these two sublineages
(Supplementary Fig. 2).
To investigate the phylogeny of these two sublineages in greater
detail we also constructed a ML phylogenetic tree using the JH/C
intron segment of all VRC26 lineage members and rooted it on
the germline IGHJ3 allele 2 (IGHJ3*02) intron. To visualize the
accumulation of intronic mutations and anchor our analysis, we
UCA exon
a b c
UCA exon UCA exon
Longitudinal time point
Number of cysteines
in CDRH3
Amino acid at kabat
position 97 of CDRH3
Gly97+disulfide
clade
Arg97+disulfide
clade
Week 38
0 Glycine
Arginine
Other
1
2
Other
Week 48
Week 59
Week 119
Week 206
0.05 0.05 0.05
Up
pe
r m
ajo
r
bi
fu
rc
at
in
g 
br
a
n
ch
N
o 
di
su
lfid
e 
bo
nd
Po
ss
ib
le
 p
re
va
le
nt
di
su
lfid
e 
bo
nd
Lo
w
e
r 
m
a
jor
bi
fu
rc
at
in
g 
br
a
n
ch
Fig. 2 Critical CDRH3-stabilizing mutations of the VRC26 lineage. a The VH exon ML tree with sequences highlighted by the longitudinal time point at
which they were isolated. b The VH exon ML tree showing the number of cysteines in the CDRH3. c Same as in b but colored with respect to the amino acid
at CDRH3 Kabat position 97
50
50
40
30
20
10
50
40
30
20
10
Naive heavy Memory heavyNaive heavy Memory heavy
L2
IGHV
a
b
c d
fe
IGHV3-30
VH+JH/C intron amplicon
VRC26 lineage JH/C intron VRC26 lineage VH gene VRC26 lineage Jλ/C intron VRC26 lineage Vλ gene
IG
JH
3 
in
tro
n 
di
ve
rg
en
ce
 (%
)
In
tro
n 
di
ve
rg
en
ce
 (%
)
V 
ge
ne
 d
ive
rg
en
ce
 (%
)
IG
JH
3-
30
 d
ive
rg
en
ce
 (%
)
IGHJ3
J genes
4 5 6 C
L2
L1
IGHJ6 C
IGHJ6 intron amplicon
L1
40
30
20
10
0
35
25
****
*
*
****
****
****
**** ****
****
****
**
**
*
15
5
38 48 59
Week
119 206 38 48 59
Week
119 206 38 48 59
Week
119 206 38 48 59
Week
119 206
0 100
Nucleotide position
downstream of IGHJ6 gene
200
Memory IGHJ6 intron
Healthy donor intron Healthy donor V gene
300 400 500 600
35
25
15
5 IG
LJ
1 
in
tro
n 
di
ve
rg
en
ce
 (%
)
IG
LV
1-
51
 d
ive
rg
en
ce
 (%
)
35
25
15
5
35
25
15
5
M
ut
at
io
n 
fre
qu
en
cy
 (%
 se
qs
)
Fig. 1 Exonic and intronic mutations accumulate in healthy donor and VRC26 B cells. a Diagram of a human heavy chain locus with a rearranged IGHJ6
gene and the IGHJ6 intron amplicon source. b A human heavy chain locus with a rearranged IGHJ3 gene with an example VH+ JH/C intron amplicon
source indicated. All VH+ JH/C VRC26 heavy chain amplicons are of the IGHJ3 rearrangement. c The intronic mutation distribution across a ~550 bp
segment directly downstream of the J gene of IGHJ6-rearranged antibodies from healthy donor mBCs (number of sequences (n)= 4796). d Germline
divergence of VH+ JH/C sequences from naive B cells and mBCs from a healthy donor. Intron divergence is shown (left) as well as the corresponding V
gene divergence (right) (Naive Heavy: n= 47,372, Memory Heavy: n= 19,704). e Intron divergence (left) and V gene divergence (right) for VRC26 heavy
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110, week 206: n= 85). Points are colored by point density using the Python Gaussian kernel density estimator function for visualization. Two-tailed
Mann–Whitney U test p-values are shown (****p-value≤ 0.0001, ***p-value≤ 0.001, **p-value≤ 0.01, *p-value≤ 0.05). Center lines on boxplots represent
the median, while the box limits represent the upper and lower quartiles and whiskers show the maximum and minimum values
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Fig. 3 Development of convergent mutations within the Gly97+ disulﬁde sublineage. a Intron-only ML tree for all VRC26 lineage members. The Gly97+
disulﬁde clade is highlighted by number of shared intronic mutations with GDS-4. Sequences labeled GDS-(1–4) were selected for expression. b The exon-
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selected an exceptionally high-quality sequence observed in more
than one dataset with relatively mutated introns from each
sublineage (GDS-4 for the Gly97+Disulﬁde sublineage and
ADS-4 for the Arg97+Disulﬁde sublineage). We then examined
the shared intronic mutations of all members of the correspond-
ing clade (Figs. 3a, 4a) and marked the respective heavy chain
sequences on the VH exon tree (Figs. 3b, 4b).
The intronic mutations of the antibodies within these two
sublineages deﬁne distinct maturation pathways (Figs. 3c, 4c),
also reﬂected in the fact that the ADS-4 and GDS-4 exons share
only three nucleotide substitutions in the VH gene. Nonetheless,
at least two CDRH3 amino acid mutations, Glu100n and Val102,
appear to have emerged independently in both sublineages at
later longitudinal time points (Figs. 3c, 4c). For example, since
many sequences from the Gly97+Disulﬁde sublineage
(including GDS-4) that share at least 6 unique intronic mutations
have either an Asp100n or Glu100n, one of these mutations likely
preceded the other (Fig. 3c). Since the Glu100n appears later in
the phylogeny in sequences with more shared intronic mutations
with GDS-4 (Fig. 3d), and at later longitudinal time points
(Fig. 3e), it likely appeared after the Asp100n. The Val102 also
appears to have developed later in the Gly97+ disulﬁde
sublineage (Figs. 3f, g). However, a similar pattern of later
independent development is evident for the Glu100n and Val102
of the Arg97+ disulﬁde sublineage (Fig. 4c–g). Outside of the
CDRH3, an Asp82a FR3 mutation also appears over time within
each of these sublineages independently (Supplementary Fig. 3).
These examples illustrate how the analysis of intronic mutations
enables the identiﬁcation of intraclonal convergence events within
highly expanded antibody lineages.
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Discovery of early neutralizing intermediates. To better
understand the development of these sublineages for neutraliza-
tion capacity, we capitalized on our knowledge of both the JH/C
intron and VH exon phylogenies. We selected sequences from
each sublineage for expression from multiple chronological stages
of the selection-free intronic phylogeny that also had their rela-
tionship supported by the VH exon tree. This is especially
important for identifying sequences that might be very early
members of each sublineage when they are difﬁcult to differ-
entiate from those of other sublineages. 31/33 of the previously
isolated VRC26 bNAbs are known to be located on the lower
major bifurcating branch and were found between week 119 and
week 206, late in lineage development. In contrast, we used our
analysis to select sequences to be the earliest (week 38–59)
characterized intermediate antibodies on the lower major bifur-
cating branch. These antibodies would not only serve as func-
tional intermediates but would provide more information about
when and how neutralization properties developed in this critical
section of the phylogeny that leads to the broadest and most
potent bNAbs.
Selected antibodies were designated as either ADS (Arg97+
disulﬁde sublineage) or GDS (Gly97+ disulﬁde sublineage) and were
recombinantly expressed to assess their potency and breadth (Fig. 5a).
Light chains were chosen by matching similar heavy and light chain
phylogenetic tree clades31 coupled with the balancing of intronic
mutation loads between heavy and light chains under the assumption
that both chains accumulate mutations at about the same rate
(Methods; Supplementary Fig. 4). Recombinantly expressed anti-
bodies were tested for neutralization of a 14-member heterologous
strain subpanel. Importantly, ADS-4, isolated at week 59 from the
Arg97+ disulﬁde sublineage, had both the Arg97 and the disulﬁde
bond and neutralized 3/14 of the heterologous subpanel strains as
well as three early week 34 autologous viruses with ~5.7% V gene
nucleotide divergence (Fig. 5b).
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Of the four antibodies that were expressed from the Gly97+
Disulﬁde sublineage, GDS-1 (week 38; having no CDRH3
cysteines) and GDS-2 (week 48; having one of the two CDRH3
cysteines), did not neutralize any of the heterologous HIV-1
strains tested but weakly neutralized week 34 autologous strains
(Fig. 5b). In contrast, GDS-3 (week 48), which contains the
CDRH3 disulﬁde bond, potently neutralized not only week 34
autologous strains but also one heterologous strain (1/14). GDS-4,
detected at week 48 with the disulﬁde bond and with ~6.4% V
gene nucleotide divergence from germline, potently neutralized
the same autologous strains as GDS-3, and additionally
neutralized 7/14 heterologous subpanel strains (Fig. 5b). GDS-4
has 7 CDRH3 mutations from the UCA other than the Cys100a
and Cys100q, only one of which, Phe100o, was unique to GDS-4
among the synthesized GDS antibodies (Fig. 5a). Thus, GDS-4
represents the earliest arising antibody displaying appreciable
heterologous neutralization breadth from the lower major
bifurcating branch (Fig. 5d).
To investigate the afﬁnity maturation of these early inter-
mediates, their binding kinetics to an early week 34 autologous
viral strain SOSIP Env trimer was assessed by SPR (Fig. 5c). The
afﬁnity of the trimer for each antibody intermediate increases
from GDS-1 to GDS-2 to GDS-3 to GDS-4, consistent with
progressive maturation. In addition, ADS-4 and VRC26.25 (the
broadest VRC26 bNAb), both of which have between 1 and 3
converging CDRH3 mutations, have the highest afﬁnity.
Sequences with diverse CDRH3s share intronic mutations. The
upper major bifurcating branch of the VH exon tree contains a
high quality sequence bearing the exon (differing in only 2 of the
ﬁrst 3 nucleotides of the FR1) of a previously-identiﬁed early
NAb, VRC26.01, that was isolated at week 59 and neutralized
20% of the viruses tested (9/46)7,26. To investigate the
VRC26.01 sublineage as we had with the Gly97+ disulﬁde and
Arg97+ disulﬁde sublineages, we highlighted members of the
VRC26.01 intronic clade based on the number of shared muta-
tions with VRC26.01 (Fig. 6a; position in the VH exon tree in
Fig. 6b).
Importantly, two antibodies from this sublineage contain a
tyrosine insertion in the CDRH3 near Kabat position 100 h
(Tyr100h), which is not present in VRC26.01. The CDRH3s of
these Tyr100h antibodies are highly diverse and differ by up to 10
amino acids from VRC26.01 (~73% identity) (Fig. 6c). However,
while the CDRH3s are divergent, these sequences share three
intronic mutations and up to 14 non-CDRH3 V gene mutations
with VRC26.01. The congruence of the intron and exon
mutational landscapes indicate that despite having highly diverse
CDRH3s, which notably included an amino acid insertion (i.e.
Tyr100h), these antibodies likely diverged from the VRC26.01
pathway before the ﬁnal A5C intronic mutation appeared. These
sequences provide an important example of how intronic
mutations can help further assess the phylogenetic relationship
of members of a lineage with highly diverse CDRH3s and where
they diverged.
Additional sequences from the same intronic clade that bear
the same founder intronic C30T mutation but do not share any
other intronic mutations with VRC26.01, may have branched off
even earlier than the Tyr100h-containing antibodies. These early-
diverging antibodies also eventually developed the Val102
CDRH3 mutation that appeared in both the Gly97+ disulﬁde
and Arg97+ disulﬁde sublineages (Fig. 6d). The presence of
antibody sequences having different intronic mutations from
those of the Gly97+ disulﬁde and Arg97+ disulﬁde sublineages
on an entirely different major bifurcating branch, reveals another
intraclonal CDRH3 convergence event.
Late-stage lineage maturation and intraclonal convergence.
From the later week 206 time point after primary infection, we
were able to ﬁnd sequences within a 97.5% exonic nucleotide
identity to the late-stage bNAb, VRC26.19, which was initially
isolated by single-B cell cloning at week 206. This bNAb was
previously shown to have a 46% neutralization breadth against 46
heterologous viruses26. Interestingly, while VRC26.19-like
sequences were isolated 206 weeks after infection, the VH exon
and intron trees revealed VRC26.19-related antibodies in the
week 119 blood sample (i.e. from nearly 2 years prior). While
these week 119 antibody CDRH3s differ by as many as 11 resi-
dues from VRC26.19 (~70% amino acid CDRH3 identity)
(Fig. 7a), there are 10 intronic SHM events (point mutations or
indels) shared between at least one member of the VRC26.19-
related week 119 and week 206 antibodies. Five of these muta-
tions (T47G, G58A, T60C, T102C and G118A) occur in an
aligned section of the introns devoid of indels and are shared
among at least two sequences found at both time points (Fig. 7b).
Some week 206 antibodies also share 23/36 V gene nucleotide
mutations with week 119 antibodies. The congruence between the
exon and intron phylogenies therefore help conﬁrm potential
heavy chain intermediates to the VRC26.19 bNAb, despite having
diverse CDRH3s (Fig. 7c).
We also found sequences within a 96.8% exonic nucleotide
identity to another bNAb, VRC26.09, previously isolated using
single-B cell cloning at week 119. VRC26.09 was also shown to
neutralize 46% of the heterologous strains tested (21/46)7,26.
Although VRC26.19-like and VRC26.09-like sequences share ~7/
36 exonic V gene mutations upstream of the CDRH3, their
CDRH3’s are highly diverse (only ~50% amino acid identity),
indicating that they diverged early on during lineage development
(Fig. 7a). The introns of VRC26.19-like and VRC26.09-like
antibodies share very few mutations, providing an additional
genetic source supporting early divergence (Fig. 7b).
The intronic mutations of VRC26.19-like and VRC26.09-like
sequences (Fig. 7b) are not only distinct from each other but are
also different from those of members of the Gly97+ disulﬁde
(Fig. 3c) and the Arg97+ disulﬁde sublineages (Fig. 4c). How-
ever, the CDRH3s across these four sets of antibodies share
amino acid mutations that likely represent additional intraclonal
convergence events including: Gln100o (Figs. 4c–h, i, 7a),
Leu100o (Figs. 3c–h, i, 7a), Pro100n (Figs. 4c–e, 7a) and Glu100n
(Figs. 3c–e, 4c–e, 7a). Like the Glu100n and Val102 mutations,
Gln100o, Leu100o, and Pro100n also become more prevalent
along the phylogeny of the Gly97+ disulﬁde and Arg97+
disulﬁde sublineages and with later longitudinal time points.
Some of these convergent mutations utilize the same or slightly
different nucleotide codons (Fig. 7d). However, the Leu100o of
the Gly97+ disulﬁde sublineage is encoded preferentially by a
TTA codon in contrast to the Leu100o of the VRC26.09-like
sequences which is encoded by a CTC codon (Fig. 7d). One or
more of these convergent mutations are retained in at least one
known neutralizing antibody. In addition, the prevalence of
replacement mutations at these sites increases over time
(Supplementary Fig. 5–6). These convergent CDRH3 signatures
may provide further information about the functional importance
of these mutations in the protruding CDRH3 loop.
Discussion
Here, we aimed to aid in the detailed understanding of the
maturation pathway of the VRC26 lineage from the CAP256
donor that targets the V1V2 region of the HIV-1 envelope. High
resolution information about bNAb evolution trajectories from a
UCA is critical for HIV-1 immunogen design. HIV-1 bNAb
lineages such as VRC26 are expansive and highly mutated and
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their reconstructed phylogenies may be difﬁcult to interpret at a
reﬁned level. To better address some of these challenges and gain
as much insight as possible into the development of the VRC26
lineage, we simultaneously sequenced the exons and introns of
lineage members. Obtaining phylogenetic information from both
the exon and the intron, the latter which is not under selection
pressure, helped us to (i) rapidly establish intraclonal convergence
within the CDRH3s of VRC26 antibodies, (ii) identify likely
intermediates for the VRC26.19 bNAb having highly divergent
CDRH3s and (iii) informatically select intermediate antibodies
with critical CDRH3 mutations and that developed heterologous
neutralization breadth several months before the earliest bNAbs
detected by single B cell cloning.
Using exonic and intronic information together, we were able
to differentiate between two important sublineages – the Arg97+
disulﬁde and the Gly97+ disulﬁde sublineage – in which the
critical Arg97, Cys100a and Cys100q CDRH3 mutations develop
and help to stabilize the long CDRH3 loop of VRC26 lineage
members. The evolution of these two sublineages had not been
explored despite their signiﬁcance in the lower major bifurcating
branch, which contains the broadest VRC26 monoclonals. The
informatically-identiﬁed GDS-3, GDS-4, and ADS-4 antibodies
are the earliest characterized VRC26 intermediates with the dis-
ulﬁde bond and/or Arg97. In addition, these antibodies appear
only ~14–25 weeks after the VRC26 lineage ﬁrst appeared in the
CAP256 repertoire. GDS-4, speciﬁcally, emerged after only
14 weeks and was able to neutralize 7/14 heterologous strains,
providing further evidence that antibodies with appreciable
breadth have the potential to be elicited soon after lineage elici-
tation. This NAb had only ~6.4% nucleotide V gene divergence
and had 7 CDRH3 mutations from the UCA other than the
Cys100a and Cys100q. The Phe100o CDRH3 mutation is the only
one unique to GDS-4 and is present at a site where intraclonal
convergence is occurring around the same time, both indicating
the possibility of this residue having a particular functional
importance. This information sets a new lower boundary of SHM
necessary to achieve breadth among lower major bifurcating
branch antibodies. The lowest previous SHM level for lower
branch bNAbs was ~9% V gene mutation26. GDS-(1–4) also
constitute a set of antibodies with increasing heterologous
breadth and increasing afﬁnity for an early week 34 autologous
strain that might be used as scaffolds for stepwise vaccine design.
Conversely, this week 34 autologous strain might also serve as an
initial complementary Env scaffold, as has been previously
suggested29.
Identifying late-stage bNAb intermediates is complicated by
the likely possibility that CDRH3s may have diverged greatly over
long maturation times, often spanning years. Understanding the
phylogenetic relationship of lineage members with highly diverse
CDRH3s has been a signiﬁcant challenge10. Using both the exon
and intron phylogenies we discovered week 119 intermediate
antibodies that preceded the development of week 206 VRC26.19
(~46% heterologous neutralization breadth) bNAb-like anti-
bodies26 nearly 2 years later. However, the CDRH3 sequences
between these week 119 and week 206 antibodies were highly
diverse with ~70% amino acid identity. Furthermore, our
approach helps conﬁrm the phylogenetic relationship of
VRC26.01 sublineage antibodies having diverse CDRH3s,
including those with a Tyr insertion. Since insertions and dele-
tions are common in bNAb lineages and may be critical for
function7,10 understanding when they emerge is of great interest.
Lastly, by using multiple sources of information, particularly
the addition of selection-free introns, we identiﬁed a number of
instances where the same CDRH3 amino acid substitutions
appear to have been selected repeatedly along different trajec-
tories, revealing intraclonal convergence. Four of these amino
acid mutations were shared with VRC26 bNAbs (VRC26.19 and
VRC26.09) that neutralize ~46% of heterologous strains, possibly
deﬁning functionally important CDRH3 convergent signatures.
In addition, two antibodies with one or more of these mutations
(ADS-4 and VRC26.25) have higher afﬁnity to a week 34 auto-
logous viral strain than the other antibodies tested without con-
vergent mutations, suggesting that the identiﬁcation of
convergent mutations might be useful for the ﬁne tuning and
optimization of more potent VRC26 bNAbs. The presence of
such convergence events during antibody maturation is very
challenging to independently conﬁrm or even identify solely by
using an exon phylogenetic analysis. The prevalence of intraclonal
convergence in other lineages and whether it is selection-driven
or a useful developmental mechanism to induce with engineered
immunogens will need further evaluation.
Methods
Healthy donor B cell isolation. About 50 mL of healthy human donor one (HD1)
or healthy donor two (HD2) source leukocytes peripheral blood (Gulf Coast
Regional Blood Center, Houston, TX, USA; E5318 product code) was used as a
source for separating all nucleated cells from red blood cells using HetaSep
(Stemcell Technologies) according to the manufacturer’s protocol. B cells were then
extracted and enriched for from the nucleated cells using an EasySep Human
CD19+ Positive Selection Kit (Stemcell Technologies) according to the manu-
facturer’s protocol. The enriched B cells were resuspended in ~500 µL of FACS
buffer. These B cells were then stained with a 1:16 dilution of anti-IgD-PE (BD,
cat#562024), a 1:16 dilution of anti-CD20-FITC (BD, cat#560962), a ~1:26 dilution
of anti-CD19-v450 (BD, cat#560353), a 1:61 dilution of anti-CD3-PerCP-Cy5.5
(Biolegend, cat#300327), and a 1:16 dilution of anti-CD27−APC (BD, cat#558664)
and then sorted for naive (CD20+CD19+IgD+CD3−CD27−) and memory (CD20
+CD19+IgD−CD3−CD27+) cells on a FACSAria II.
CAP256 donor. The CAP256 donor was initially enrolled in the Centre for the
AIDS Programme of Research in South Africa (CAPRISA) 002 Acute Infection
Study32 in KwaZulu-Natal, South Africa in 2004 and samples were drawn between
2005 and 2009. The CAPRISA 002 Acute Infection study complied with all relevant
ethical regulations and was approved by the ethics committees of the University of
KwaZulu-Natal (E013/04), the University of Cape Town (025/2004) and the
University of the Witwatersrand (MM040202). Donor CAP256 provided written
consent for the initial study.
Genomic DNA isolation. Genomic DNA was extracted from CAP256 longitudinal
samples of total PBMCs using an AllPrep kit (Qiagen) following the manufacturer’s
protocol. The number of cells used for each CAP256 longitudinal time point is
listed in Supplementary Table 1. All CAP256 gDNA samples were eluted into
100–200 µL of deionized water. HD1 and HD2 gDNA was isolated using a DNeasy
kit (Qiagen) and eluted into 100 µL of elution buffer. Each column was used for a
second elution into another 100 µL of elution buffer to collect the remaining
gDNA.
Generation of monoclonal control plasmid template. A human lambda light
chain monoclonal control plasmid consisting of a Vλ+ Jλ/C amplicon (using
IGLV1–51and IGLJ1 germline genes) was ampliﬁed from ~150 ng of HD2 gDNA
using the primers in Supplementary Table 5. Ampliﬁcation was done with NEB HF
Phusion Polymerase with the outer control generating primers used for the ﬁrst
PCR and the IGLV1–51 leader peptide forward and IGLJ1 300 series reverse pri-
mers used for the nested PCR. This amplicon was then cloned and Sanger
sequenced.
High-throughput sequencing. All samples prepared for high-throughput
sequencing require a ﬁrst round PCR of 35 cycles followed by a nested PCR of 25
cycles. The following PCR program is the same for almost all ﬁrst round and nested
PCRs: 98 oC for 5 mins for initial denaturation, 98 oC for 30 s, 55 oC for 30 s, 72 oC
for 30 s, and a ﬁnal extension step of 72 oC for 7 mins and cooled to 4 oC.
Annealing temperatures were lowered to 50 oC for the HD1 heavy chain multiplex
PCRs. All PCR recipes consist of the following per 25 µL of reaction volume: 5 µL
of 5x Phusion Buffer (NEB), 0.5 µL of 10 mM each dNTP mix (NEB), 0.25 µL of HF
Phusion Polymerase (NEB) with forward primers, reverse primers, water and
template constituting the remaining volume. All ﬁrst round PCRs utilize forward
primers for one or multiple L1 leader peptides while the reverse primer consists of
one or more of the 300 series outer intron primers. First round products were
consolidated with a DNA cleanup kit (Zymo; with multiple columns if necessary)
and diluted 1:10 with 1 µL of this product being used as template per 25 µL of
nested PCR reaction volume. All nested PCRs utilize one or multiple FR1 forward
primers and one or more of the 250 series inner intron primers. Nested products
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were cleaned up and consolidated once more and were gel-puriﬁed for sizes
~450–600 bp. Each sample received an overall total of 60 cycles before standard
Illumina library prep and addition of adapters, followed by Illumina MiSeq 2 × 300
paired-end sequencing.
The lambda monoclonal control sample for high-throughput sequencing was
prepared from 80 ng of the generated monoclonal control plasmid template using
the FR1 and 250 series primers in Supplementary Table 5. For ampliﬁcation of the
non-monoclonal healthy donor samples (HD1 source gDNA) and VRC26
longitudinal samples, ~200–250 ng of gDNA was used per 25 µL of ﬁrst round PCR
reaction volume. The primers used for the HD1 memory and naive repertoires are
listed in Supplementary Table 6. All heavy chain VRC26 ﬁrst round PCRs used the
same L1 leader peptide and 300 series outer intron primer. The ﬁrst round PCR
primers for light chain VRC26 samples are also the same for all time points. The
FR1 forward primers used in the nested PCR for each heavy or light chain
longitudinal time point were designed to take into account the most prevalent FR1
mutations found in the ﬁnal datasets of the previously reported RNA-derived
sequences7,26. Supplementary Data 1 lists the intron and leader peptide primers
used for the heavy chain samples along with the FR1 sequences used for the Part I
ampliﬁcation of sequences which utilized only a limited number FR1 nested
primers and resulted in the datasets marked as “I” in Supplementary Table 3. A
second round of nested PCRs were performed from the ﬁrst PCR template utilizing
the Part II primers listed in Supplementary Data 1 and are marked as the “II”
datasets in Supplementary Table 3. A select few of these prepped Part I and Part II
datasets were re-sequenced as technical replicates to get a higher read coverage and
are marked with an additional “-II” in Supplementary Table 3. All VRC26
longitudinal light chain datasets were only generated and sequenced once with the
primers listed in Supplementary Data 1 and with the ﬁnal sequencing datasets
listed in Supplementary Table 4.
The human mBC IGHJ6 intron amplicons were generated by amplifying with a
heavy chain FR1 multiplex primer set with a downstream IGHJ6 intron-speciﬁc
primer in the ﬁrst PCR. A subsequent nested PCR was performed with an IGHJ6 J
gene-speciﬁc primer and a nested IGHJ6 intron primer to generate amplicons of
IGHJ6 introns that correspond to cells carrying a rearranged IGHJ6-utilizing
antibody sequence. The primers that were used are listed in Supplementary Table 7.
Bioinformatic curation of VRC26 lineage members. Raw MiSeq paired-end
reads from the VRC26 heavy chain samples were stitched together using the PEAR
(v0.9.10) (http://sco.h-its.org/exelixis/web/software/pear/) paired-read stitching
program. FASTX-Toolkit (v36.06) (http://hannonlab.cshl.edu/fastx_toolkit/) was
then used to ﬁlter for reads that have a quality score of 20 for ≥90% of the read.
Sequences were then annotated with IMGT High V-Quest (http://www.imgt.org/
HighV-QUEST/)33. Reads were retained that aligned to the VRC26 germline V
gene (IGHV3–30; as well as IGHV3–30–3 or IGHV3–30–5 to avoid ﬁltering out
incorrectly annotated somatic variants) and germline J gene (IGHJ3) ignoring
alleles and keeping those that possessed all four framework regions and all three
CDRs, and that were productive.
For each longitudinal time point (including Part I and Part II datasets), blastn
from BLAST+ (version 2.2.28+ ) (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was
used to isolate potential VRC26 lineage members by querying for all unique
nucleotide CDRH3 sequences from the previously published datasets7,26.
Sequences that had a nucleotide CDRH3 sequence within 85% identity and 99%
query coverage (to allow for soft-clipping) (-max_target_seqs 5000 to ensure full
coverage of each database, word size of 28 (default)) to the previous
CDRH3 sequences were retained. These sequences were then ﬁltered for only those
that contained exact matches for both the forward and reverse primer sites, sorted
by abundance (in decreasing order) and then clustered to 96% identity with
USEARCH (v8.1.1861) (-sortedby size –maxaccepts 0 –maxrejects 0)34. A human
lambda light chain monoclonal control (545 bp length amplicon) served to help set
the 96% clustering identity cutoff and showed that at least 99.98% of control
sample sequences that were able to be aligned with bowtie2 (v2.2.6) (http://bowtie-
bio.sourceforge.net/bowtie2/manual.shtml) with an end-to-end alignment were
within 96% identity to each other based on their PCR/sequencing error rates
(ignoring indels). These alignments were done only after the monoclonal control
sequence dataset had undergone the earlier ﬁltering steps to assess the required
stringency of clustering only after those previous steps. This is comparable to that
used by others7,10,26. Only the sequences of the centroids of each cluster output by
USEARCH that had a cluster size of more than two members were selected for
further processing. These sequences were then aligned using MAFFT (version
v7.215) (http://mafft.cbrc.jp/alignment/software/)35 (–auto) and manually curated
to remove those that had external insertions outside the primer site or that were
missing the majority of the intron portion of the read. Only sequences that
possessed a CDRH3 matching the Python regular expression C[A-Z]{10,40}WG.G
were retained (Supplementary Table 3). The previously inferred UCA sequence7
was concatenated to a primer-dictated germline segment of the IGHJ3*02 intron
and was inserted into this FASTA ﬁle along with all identiﬁed and marked triple
replicate sequences (see Triple replicate sequence identiﬁcation). For certain
analyses, sequences that were likely PCR chimaeras were also excluded when they
could be identiﬁed.
The variable region was translated and aligned in amino acids by MAFFT and
then reverse translated and re-concatenated to the nucleotide alignment by MAFFT
of the intron sequences. The forward and reverse primer sites were then clipped
since they are degenerate. One hundred partitioned maximum likelihood trees were
then generated using RAxML (version 8.0.26) (http://sco.h-its.org/exelixis/web/
software/raxml/)36 using the provided GTRCAT approximation. This was done for
the variable region alone, the intron alone and by partitioning on both the coding
variable region and the non-coding intron region separately. The ﬁnal trees were
optimized under the GAMMA model and the tree with the best likelihood score
was used for further analysis. Trees were then visualized with FigTree (http://tree.
bio.ed.ac.uk/software/ﬁgtree/) and rooted onto the previously inferred UCA, the
IGHJ3 intron or the UCA concatenated to the IGHJ3 intron (UCA+ JH3/C) and
ladderized right.
The same procedure was followed for the VRC26 lambda light chain samples
except all sequences annotated to the VRC26 germline genes, IGLV1–51 and
IGLJ1, were extracted. Sequences with a 92% CDRL3 nucleotide identity to
previously published VRC26 light chain sequences7,26 were assumed to be
members of the lineage since CDRL3s are shorter and less variable. Only one
partition tree was generated for the light chain members and the previously
inferred light chain UCA7 was used to root this tree after being concatenated to the
primer-dictated IGLJ1*01 intron sequence segment. Sequences were ﬁltered for
those containing a CDRL3 motif C[A-Z]{5,20}F within the last 40 amino acids of
the exon (Supplementary Table 4). The same basic ﬁltering and curation steps were
also used for all healthy donor samples (Supplementary Table 2). However, the
HD1 naive sample did not use the maxrejects= 0 or maxaccepts= 0 clustering
termination conditions due to computational intensity.
Intron allele identiﬁcation for the VRC26 lineage. The VRC26 lineage germline
heavy chain J gene is IGHJ3. There are only two known human IGHJ3 gene exon
alleles (IGHJ3*01 and IGHJ3*02). From the IMGT genetic sources, we were able to
identify two intronic variants for each of these alleles, which are differentiated by
indels or point mutations (Supplementary Data 1). IGHJ3*02 was previously
thought to be the J gene allele during the initial recombination event for the VRC26
lineage7. All intron sequences of ﬁnal VRC26 lineage members have a higher
identity to IGHJ3*02 Variant 1 than any of the other three variants, except two
sequences that, when manually examined, match more appropriately with
IGHJ3*02 Variant 1, as expected. Importantly, of the VRC26 lineage sequences,
~50 exact germline IGHJ3*02 Variant 1 allele introns could be found, while none
exactly matched any of the other IGHJ3 intronic variants. Likewise, an intron
alignment of all IGHJ3 sequences from a CAP256 week 38 dataset (not just from
the VRC26 lineage) against IGHJ3*02 Variant 1 showed that all sites mutated
~10% or less except for site 114 at ~50%, indicating that this is only potential site
for intronic heterozygosity, with most sequences having either a C or G. All triple
replicate sequences and most sublineage sequences have no mutations at this site.
Similarly, the VRC26 germline light chain J gene is IGLJ1*01, of which there is only
one known allele, and of which we could identify only one full length variant
(Variant 1) (Supplementary Table 8). ~30 sequences with introns exactly matching
that of the known IGLJ1*01 Variant 1 were found in the ﬁnal VRC26 lineage light
chain sequences. An alignment of all IGLJ1 sequences from a CAP256 week 38
dataset (including sequences from outside the VRC26 lineage) against IGLJ1*01
Variant 1 shows all sites ~30% mutated or lower, with the highest peaks appearing
only at hotspots, suggesting intronic homozygosity.
Triple replicate sequence identiﬁcation. All sequences identiﬁed from each of
the sequenced datasets with a ≥98% nucleotide identity and ≥99% query coverage
(blastn) to members of the Doria-Rose et al. 2014, 2016 datasets7,26 were extracted.
Any of these sequences (excluding primer sites) that had duplicate reads in two or
more gDNA-derived MiSeq datasets were isolated as those of the highest quality
since they have a high identity to members of previously reported RNA-derived
datasets and have exact replicates present in gDNA-derived datasets generated
through different nested PCRs (Part I and Part II datasets) or re-sequencing (-II
datasets). Only gDNA-derived sequences that unambiguously matched with an
RNA-derived sequence were considered. If there were multiple matches to an
RNA-derived sequence, only those of the highest identity to the RNA-derived
sequences were considered. GDS-4 and VRC26.01 fulﬁll these requirements. While
ADS-4 is found with an exact match only within the same dataset, its exon is also
found in the previously published RNA-derived raw data from week 59 with only a
single nucleotide substitution in the CDR2.
Selection of heavy and light chains for expression. Sequences from the Gly97+
disulﬁde and Arg97+ disulﬁde sublineages with various numbers of shared
intronic mutations with either GDS-4 or ADS-4 were chosen for expression to
represent the stages of the evolution of each sublineage as best as possible, while
minimizing the presence of unshared intronic mutations and investigating various
CDRH3 molecular traits. These sequences also exhibited a general phylogenetic
relationship in the VH exon tree. Each of these antibodies is labeled as either GDS
(Gly97+ disulﬁde) or ADS (Arg97+ disulﬁde) with a number.
To estimate complementary light chains for the expression of the selected GDS
and ADS heavy chains, we utilized the Vλ+ Jλ/C partition ML light chain tree and
the VH+ JH/C partition ML heavy chain tree to incorporate as much genetic
information as possible into single trees for pairing phylogenetic branches.
Examination of the Vλ+ Jλ/C partition light chain tree revealed two major
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bifurcating branches similar to that of the heavy chain. The lower light chain major
bifurcating branch contains sequences with high identity to the light chains of
VRC26.01 and VRC26.24 (Supplementary Fig. 4) along with 6/7 triple light chain
replicates, all of which are thought to have appeared early in the lineage7,26. This
suggests that the lower light chain major bifurcating branch is associated with the
upper major bifurcating branch of the heavy chain tree. We therefore reasoned that
the upper major bifurcating light chain branch corresponded to the lower major
bifurcating heavy chain branch (where the chosen heavy chain sequences are
located). There are few week 119 and week 206 light chain sequences and many of
these appear in the upper major bifurcating branch of the light chain tree,
providing further evidence for this reasoning.
We reasoned that the two strongly deﬁned light chain clades of the upper major
bifurcating branch might correspond to the strongly deﬁned clades that represent
the Arg97+ disulﬁde and Gly97+ disulﬁde sublineages. We reasoned that the
more extensively mutated Gly97+ disulﬁde sublineage clade might correspond to
the more mutated of these light chain clades, while the less mutated Arg97+
disulﬁde sublineage clade might correspond to the less mutated of these light chain
clades (Supplementary Fig. 4).
For a given heavy chain sublineage, all sequences from the matching light chain
clade were binned into intronic divergence levels, and any that had a corresponding
divergence to the chosen heavy chain sequence were selected as potential
complementary light chain candidates. From these candidates, the sequence
sharing the highest number of intronic mutations with the most intronically-
mutated sequence furthest along in the light chain clade topology was chosen to
help retain the phylogeny of the light chain clade as closely as possible. If there
were multiple candidates from this pool that met these two criteria, one was chosen
at random (using the random module implemented in Python 2.7.6).
Antibody expression. Sequences for heavy and light chains were codon optimized
for mammalian expression, synthesized (GenScript), and cloned in the pVRC8400
vector. Equal amounts of heavy and light chain plasmid were co-transfected with
Expi293F cells (Thermo Fisher) according to the cell manufacturer’s directions.
Following a 6-day incubation, cells were pelleted by centrifugation and supernatant
was ﬁltered through 0.22 μm Stericup ﬁlter units (EMD Millipore) and then applied
to a column containing a 2 mL bed of Protein A Sepharose Fast Flow (GE
Healthcare, Chicago, IL) equilibrated with PBS. The column was washed with
Protein A IgG Binding Buffer, and antibody was eluted with Pierce IgG Elution
Buffer (Thermo Scientiﬁc) and pH neutralized with 1 M Tris pH 8 solution.
Antibodies were buffer-exchanged to PBS overnight using 10,000 MWCO dialysis
cassettes (Thermo Fisher).
Silent and replacement mutation plots. All VRC26 heavy chain lineage
sequences were aligned as amino acids and this alignment was then reverse
translated into a nucleotide alignment. Sequences were split into their respective
time points and all sequences were compared to the UCA (including the CDRH3)
to determine silent and replacement mutations. Indels were ignored for this ana-
lysis. Their frequency was plotted as the percent of sequences in each time point
containing this mutation.
Generating divergence plots. To generate the healthy donor divergence plots,
only curated sequences were used. The introns from these sequences were aligned
with MAFFT to each of the relevant germline introns, with the lowest divergence
value generated from each of these alignments taken to be the ﬁnal value. Intronic
divergence was calculated as the number of SHM events (number of point
mutations+ number of indel events) divided by the length of the germline intron
portion of a theoretical amplicon (excluding the primer site). V gene divergence
values were calculated using IMGT annotated V gene mutations. The most pre-
valent alleles by exact match read counts in the naive dataset were used. The same
procedure was used for the VRC26 lineage longitudinal divergence plots, except
these plots are generated from all datasets corresponding to a single time point
alone and then curating with pooling across time points. All of these sequences
were aligned only to the IGHJ3*02 Variant 1 intron or to the IGLJ1*01 Variant 1
intron, which were chosen as described in Intron allele identiﬁcation for the
VRC26 lineage.
IGHJ6 intron mutation distribution plot. The IGHJ6 intron mutation distribution
frequency plot was generated using the same ﬁltering stringency as other samples
except without IMGT ﬁltering steps. Sequences were clustered using USEARCH to
a 96% identity (centroids only taken from clusters with more than two members)
and were required to have exact primer matching. Sequences were aligned using
MAFFT (–auto) to the germline IGHJ6*03 Extended Variant 1 allele sequence to
determine the mutation frequency at various sites. This allelic variant was chosen
since HD1 alignments indicate the donor is likely heterozygous for IGHJ6*03
Extended Variant 1 and IGHJ6*02 Extended Variant 2 (Supplementary Data 1)
with a single nucleotide polymorphism at site 121.
Neutralization assays. Env pseudoviruses were generated through the cotrans-
fection of a pSG3ΔEnv backbone plasmid and a plasmid encoding a full Env gp160
in a 3:1 ratio in 293 T cells using the FuGENE transfection reagent (Promega).
Media was replaced the day following transfection and cells were allowed to
incubate overnight once more. The next day the media was then ﬁltered with a
0.45 µm Steriﬂip unit (EMD Millipore) to collect pseudovirus. 40 µL of diluted
pseudovirus was mixed with 10 µL of serially-diluted antibody and incubated for
30 min at 37 °C. 20 µL of TZM-bl cells at a concentration of 10,000 cells/well were
then added and incubated overnight at 37oC with or without DEAE-Dextran. 100
µL of fresh DMEM was added and the samples which were once again incubated
overnight. 50 µL of Steadylite Plus Reporter Gene Assay System (PerkinElmer) was
then added, plates were shaken for 15 min and luminescence was measured.
Neutralization data is reported as IC50 values (µg/mL) and were calculated from
measuring the reduction in luminescence by the addition of various dilutions of
each antibody. Percent inhibition was deﬁned as 100 times the difference in average
RLU between cell only controls and samples with antibodies added divided by the
difference in average RLU between virus controls and cell only controls.
The pseudoviruses used for these assays included heterologous strains from
Clade A (BB201.B42, BG505.W6M.C2, KER2008.12, KER2018.11, Q23.17),
Clade AE (CM244.ec1), Clade AG (T250–4), Clade B (WITO.33), Clade BC
(CH070.1), Clade C (CAP210.E8, ZM197.7, ZM233.6, ZM53.12), and Clade D
(3016.v5.c45)7,26. Pseudoviruses also included autologous strains from week 34
(CAP256.3.11.80, CAP256.3.11.81, CAP256.3.11.77, CAP256.3.11.18, and
CAP256.3.11.22), week 38 (CAP256.3.12.38), week 48 (CAP256.3.14.8,
CAP256.3.14.17, CAP256.3.14.18), week 59 (CAP256.3.16.2, CAP256.3.16.4, and
CAP256.3.16.10b), week 94 (CAP256.4.19.A3, CAP256.4.19.F4) or the
superinfecting strain (CAP256.206.C9)29.
Surface plasmon resonance. Binding of CAP256.3.11.80 SOSIP Env trimer to
VRC26 lineage members (UCA, GDS-(1–4), ADS-4 and VRC26.25) was measured
by SPR with single-cycle kinetics. Antibodies were captured on an anti-Fc surface
and Env trimer was ﬂowed at 50 ml/min in HBS-EP buffer. Concentrations of Env
trimer ranging from 1 nM to 500 nM were measured in a single cycle dilution series
and adjusted within the afﬁnity limits of each lineage member.
Statistical analysis. Two-tailed Mann–Whitney U statistical tests (assuming non-
normality, independent groups and observations, ordinal or continuous dependent
variable) were performed using the implemented Mann–Whitney U test function
made available through the scipy.stats module of Python 2.7.6.
Code availablity. Custom scripts have been deposited in GitHub.
Data availability
Raw sequencing datasets for all samples have been deposited in the NCBI Short Read
Archive under accession code SRP124539. Synthesized monoclonal antibody sequences
and intermediate sequences have been deposited in Genbank under accession codes
MH409941-MH409952. VRC26 heavy and light chain lineage sequences have been
deposited in Genbank under accession codes MH407745-MH409383 and MH409384-
MH409940. Raw FACS data has been deposited in FlowRepository under ID FR-FCM-
ZYPZ.
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